Trump’s prescription drug executive order rollback didn’t quash all Biden-backed cost savings
The executive order, which Biden signed in October 2022, had not spurred any lower drug prices by the time Trump revoked it Jan. 20. The order directed the Health and Human Services Department secretary to consider "new health care payment and delivery models" for the Center for Medicare and Medicaid Innovation to test.
Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that would require price disclosures on advertisements for prescription drugs. The bill would ...
Since the announcement that president-elect Donald Trump would nominate Robert F. Kennedy Jr. (RFK Jr.) as the secretary of the U.S. Department ...
The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for elamipretide for the treatment of Barth syndrome, a rare genetic disorder.
The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.
The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.
The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) for the treatment of adults with locally advanced ...
WASHINGTON U.S. Senate Democratic Whip Dick Durbin (D-IL) and U.S. Senator Chuck Grassley (R-IA), senior member and former ...
and substance use disorder, CMS said. Since April 1, 2023, people with Medicare have seen savings on over 120 drugs thanks to Inflation Reduction Act’s Medicare Prescription Drug Inflation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback